Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tourmaline Bio, Inc. (TRML : NSDQ)

• Company Description    Tourmaline Bio Inc. is a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases. The company's lead program includes TOUR006. Tourmaline Bio Inc., formerly known as Talaris Therapeutics Inc., is based in NEW YORK. Number of Employees: 74

• Price / Volume Information    Yesterday's Closing Price: $47.61 Daily Weekly Monthly 20 Day Moving Average: 1,560,002 shares Shares Outstanding: 25.69 (millions) Market Capitalization: $1,223.20 (millions) Beta: 2.04 52 Week High: $47.70 52 Week Low: $11.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 112.64% 108.90% 12 Week 182.89% 156.96% Year To Date 134.76% 109.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 27 WEST 24TH STREET SUITE 702 - NEW YORK,NY 10010 USA ph: 646-481-9832 fax: - lstern@meruadvisors.com http://www.tourmalinebio.com

• General Corporate Information    Officers Sandeep Kulkarni - Chief Executive Officer and Director Clay Siegall - Chairman of the Board Ryan Robinson - Chief Financial Officer Caley Castelein - Director Aaron Kantoff - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 89157D105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 25.69 Most Recent Split Date: 10.00 (0.10:1) Beta: 2.04 Market Capitalization: $1,223.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.96 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -32.35% vs. Previous Quarter: -1.12% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -30.50 03/31/25 - -26.75 12/31/24 - -22.29 ROA 06/30/25 - -29.63 03/31/25 - -26.11 12/31/24 - -21.83 Current Ratio 06/30/25 - 24.68 03/31/25 - 33.87 12/31/24 - 30.18 Quick Ratio 06/30/25 - 24.68 03/31/25 - 33.87 12/31/24 - 30.18 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 10.09 03/31/25 - 10.90 12/31/24 - 11.71 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©